Drug intelligence / Profile preview

Glandosane

Development stage: Unknown
Lead developer: Cell Pharm
Administration: Topical

Overview

**Glandosane** is a locally acting synthetic saliva substitute supplied as an oral spray for symptomatic management of xerostomia. Its carmellose sodium-based, electrolyte-containing formulation is designed to approximate the physical and chemical properties of natural saliva and to moisten the oral and pharyngeal mucosa. It is used for dry mouth of varied causes, including xerostomia associated with head-and-neck radiotherapy. ([medikamente.basg.gv.at](https://medikamente.basg.gv.at/documents/16749__DOTC_FACH_INFO.pdf))

Brand names: Glandosane
Other names: Glandosane synthetischer Speichel

Beyond the preview

Go deeper on Glandosane.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Glandosane.

Explore the full profile